21 Jan 2021 – Destiny Pharma Investor Presentation

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

 Investor Presentation

Brighton, United Kingdom – 21st January 2021 – Destiny Pharma plc (AIM: DEST, “the Company”) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce that Neil Clark and Shaun Claydon will deliver a live presentation introducing Destiny Pharma via the Investor Meet Company platform on 27th January 2021 at 11:00 am GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Destiny Pharma via:

https://www.investormeetcompany.com/destiny-pharma-plc/register-investor 

Investors who already follow Destiny Pharma on the Investor Meet Company platform will automatically be invited.

Enquiries:

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)

finnCap Limited – Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)
 

WG Partners LLP – Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig 

Optimum Strategic Communication

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information, please visit https://www.destinypharma.com